Kymera Therapeutics (NASDAQ:KYMR) jumped 16% on Monday after the company reported promising early-stage clinical results for KT-621, its oral STAT6 degrader being developed for moderate to severe atopic dermatitis.
Data from the Phase 1b BroADen study showed that KT-621 delivered substantial STAT6 degradation in both the 100 mg and 200 mg dosing groups, with median reductions of 94% in skin tissue and 98% in blood samples. The therapy also generated meaningful clinical improvements, including an average 63% drop in Eczema Area and Severity Index (EASI) scores and a 40% reduction in peak itch intensity among all treated participants.
Participants with asthma as a coexisting condition saw additional benefits, posting a median 56% decline in fractional exhaled nitric oxide (FeNO) and reporting better overall asthma control. Those with allergic rhinitis also experienced notable symptom relief and improved quality of life.
The safety profile was favorable, with no serious adverse events, no treatment-related adverse events, and no occurrences of conjunctivitis. Vital signs, laboratory values, and ECG results remained stable throughout the study.
KT-621 also reduced key Type 2 inflammatory biomarkers, including a 74% median drop in TARC (thymus and activation-regulated chemokine) levels among patients whose baseline values mirrored those seen in dupilumab clinical trials for atopic dermatitis.
Kymera said its BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis is ongoing, with results expected in mid-2027. A separate Phase 2b study in moderate to severe asthma, known as BREADTH, is slated to begin in the first quarter of 2026.